Join us as we go over our top stories from the week:
Chinese Patient Organizations Eye Greater Participation in Drug Development.
Chinese Biotech’s Herceptin Biosimilar Meets Endpoint & Moves Closer to Approval One of the World’s Largest Private Equity Firms Enters Targets Unmet Need for Bladder Cancer with Swiss Pharma.
‘Catch Me if you Can’: Poser Investigator Bills Big Clinical Sponsors, Dupes CRO, While Endangering Patient Lives.
Ohio State University Developed Drug Receives FDA Approval for Treatment of CLL and SLL.
Researchers from Scotland, Australia & Malaysia Show Success with Blocking Transmission of Dengue Fever.
Stephenson Cancer Center OU Receives U.S.
DOD Grant to Investigate Lung Cancer Cell Avoidance & Immunotherapy. Medical University of South Carolina Uncover New Way to Inhibit Colorectal Tumor Growth.
Clinical Trials May Be Next Best Option with Hidradenitis Supperativa.
Global Blood Therapeutics Announces FDA Approval of Oxbryta for Sickle Cell Disease Acadia Pharma Reports Positive Data from Phase 2 ADVANCE Trial Pimavanserin for Negative Symptoms of Schizophrenia.
Karolinska Institutet & Academic Specialist Center Sweden to Launch Clinical Trial for Temelimab in MS Patients. Clinical Trial Concerning Complexity of Cancer in Autoimmune Compromised Patients.
Stalin Adverse Event Monitoring Clinical Trial Powered by Silicon Valley-based Mobile App Platform.
Upadacitinib Appears to Help Ankylosing Spondylitis Patients During Phase II Trial.
Mission to Combat Brain Tumors Starts with UK-based Brain Tumor Research.
UCSF’s Move to Make Clinical Research more Inclusive for Underrepresented Patients: The Trial Site Library.
University of Birmingham Study Analyzes Trials Evidencing Value in Pharmacists-Led CVD Interventions in Health System.